Latest News for: dbv

Edit

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (DBV Technologies SA)

Public Technologies 16 Jan 2026
2https.//dbv-technologies.com/press_releases/dbv-technologies-announces-financing-of-up-to-306-9-million-e284-5-million-to-advance-viaskin-peanut-patch-through-biologics-license-application-submission-and-u-s-commercial-launch-if-appr/.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (DBV Technologies SA)

Public Technologies 14 Jan 2026
DBV Technologies S.A ... ("Life Sciences" and together with 667, the "Funds") exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a "BS Warrant") of DBV Technologies S.A.
Edit

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (DBV Technologies SA)

Public Technologies 07 Jan 2026
DBV TECHNOLOGIES ... Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF. DBV Technologies (Euronext. DBV - ISIN ... 74,580 DBV Technologies shares, € 527,891.63 ... 41,159 DBV Technologies shares, € 432,367.25 ... About DBV Technologies ... DBV.
Edit

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Nasdaq Globe Newswire 07 Jan 2026
AMF Regulated Information. Ch�tillon, France, January 7, 2026 ... .
Edit

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years (Form 8-K) (DBV Technologies SA)

Public Technologies 16 Dec 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years • ... DBV to host a conference call today at 5.00 p.m ... DBV Technologies (Euronext. DBV - ISIN ... DBV, ISIN code.
Edit

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (DBV Technologies SA)

Public Technologies 03 Dec 2025
DBV Technologies SA published this content on December 02, 2025, and is ...
Edit

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years (DBV Technologies SA)

Public Technologies 12 Nov 2025
DBV TECHNOLOGIES ... DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year ... DBV.
Edit

Initial Statement of Beneficial Ownership (Form 3) (DBV Technologies SA)

Public Technologies 12 Nov 2025
) FORM 3 ... 3235-0104 ... DBV Technologies S.A ... C/O DBV TECHNOLOGIES S.A., 107 AVENUE DE LA REPUBLIQUE 4 ... C/O DBV TECHNOLOGIES S.A ... DBV Technologies SA published this content on November 12, 2025, and is solely responsible for the information contained herein.
Edit

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (DBV Technologies SA)

Public Technologies 05 Nov 2025
‌DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference. DBV Technologies (Euronext. DBV - ISIN ... About DBV Technologies ... DBV Technologies is committed to transforming the care of food allergic people.
Edit

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer (DBV Technologies SA)

Public Technologies 04 Nov 2025
DBV Technologies SA published this content on November 03, 2025, and is ...
Edit

DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial (DBV Technologies SA)

Public Technologies 04 Nov 2025
DBV Technologies SA published this content on November 03, 2025, and is ...
Edit

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025 (DBV Technologies SA)

Public Technologies 04 Nov 2025
DBV Technologies SA published this content on November 03, 2025, and is ...
Edit

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (DBV Technologies SA)

Public Technologies 04 Nov 2025
DBV Technologies SA published this content on November 03, 2025, and is ...
Edit

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Nasdaq Globe Newswire 03 Nov 2025
Chatillion, France, November 3, 2025 ... .
Edit

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq (DBV Technologies SA)

Public Technologies 30 Oct 2025
DBV Technologies SA published this content on October 29, 2025, and is solely ...

Article Search

tools
×
×
×
×